Physician profile
Edna Thompson
NPI 1477991669
$2,367.84
in general payments reported to CMS, 2019-2025
13 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $356 · 2023: $674 · 2024: $375 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $363.29 | 2021-2023 | Spravato |
| Abbvie INC. | $340.01 | 2023-2025 | |
| Glaxosmithkline, LLC. | $337.54 | 2023 | Arexvy |
| Genentech USA, INC. | $246.17 | 2021-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $215.32 | 2022-2025 | Austedo Xr |
| Janssen Biotech, INC. | $131.38 | 2024 | Tremfya, Stelara |
| Optinose US, INC. | $125.00 | 2025 | |
| Grifols USA, LLC | $124.98 | 2022 | |
| Vanda Pharmaceuticals INC. | $124.98 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $121.82 | 2024 | |
| Axsome Therapeutics, INC. | $108.01 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $77.68 | 2025 | |
| Esperion Therapeutics, INC. | $51.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edna Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.